Abstract: Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.

Abstract: A system for endoscopic ultrasound guided drainage includes an access sheath including an elongated tube extending longitudinally from a proximal end to a distal end and including an access lumen extending therethrough from the proximal end to the distal end and a flexible tip coupled to the distal end of the elongated tube, the flexible tip biased to a curved configuration. The system also includes a sharp slidably received within the access lumen, the sharp extending longitudinally from a proximal end to distal end and including a channel extending therethrough, the channel configured to receive a fluid therethrough. In addition, the system includes a dilating sheath extending longitudinally from a proximal end to a distal end and including a dilating lumen extending therethrough, the dilating lumen sized and shaped to slidably receive the access sheath. The dilating lumen is sized and shaped to slidably receive the access sheath.

Abstract: Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: Described herein are armour panels that can be used to protect entities such as vehicles, buildings or organisms from overpressure either in the form of an explosion (shockwave) or projectile (bullet, shrapnel etc). In particular, the invention relates to the use of a combination of layers to form a panel with pressure impulse mitigating properties to provide an armour panel which is lightweight, cheap to manufacture and yet strong enough to withstand impact from high velocity ballistics, fragments and the like.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.

Abstract: A multilayer armored panel comprising: (I) at least one layer that is non moldable when dry but moldable when wet; (II) at least one hydrogel based layer in contact with layer (I) which, when wet enables the molding of layer (I) but which is capable of drying out to leave a non moldable layer (I).

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: A multilayer armored panel comprising: (I) at least one layer that is non moldable when dry but moldable when wet; (II) at least one hydrogel based layer in contact with layer (I) which, when wet enables the moulding of layer (I) but which is capable of drying out to leave a non moldable layer (I).

Abstract: Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.

Abstract: Adapters for attaching a device to a port and methods of use thereof are disclosed. The adapter may include a housing to receive the device, wherein the housing includes an inner cavity configured to receive the port, and a sealing member; and an engaging member coupled to and moveable relative to the housing, the engaging member configured to move between a first position and a second position, where in the first position the engaging member locks the housing to the port, and in the second position the engaging member unlocks the housing from the port.

Abstract: A biopsy device includes a needle extending longitudinally from a proximal end to a distal end and including a channel extending therethrough and a stylet extending through the channel of the needle and including a coil at a distal end thereof such that rotation of the stylet relative to the needle moves the coil from a closed configuration in the channel to a tissue collecting configuration in which the coil extends distally past the distal end of the needle to be inserted into a target tissue.

Abstract: A device for use in conjunction with a medical device comprises a handle extending longitudinally from a proximal end to a distal end and including a lumen extending therethrough for accommodating a longitudinal probe. A distal end of the handle including a coupling for attachment to a proximal end of a needle device. The handle includes a length adjusting mechanism enabling a user to set a length of the handle at a desired length and a flexible probe sized and shaped for insertion through a lumen of the medical device. A length of the probe is selected relative to a length of the lumen within which it is to be employed so that, when the length of the handle is set at a desired length, insertion of the flexible probe through the lumen to a distal-most position extends a distal portion of the probe distally beyond the distal end of the lumen by a desired distance.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.